D.A. Davidson & CO. Boosts Stock Position in Axon Enterprise, Inc. (NASDAQ:AXON)

D.A. Davidson & CO. grew its stake in Axon Enterprise, Inc. (NASDAQ:AXON) by 50.7% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 12,503 shares of the biotechnology company’s stock after purchasing an additional 4,208 shares during the period. D.A. Davidson & CO.’s holdings in Axon Enterprise were worth $3,230,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also made changes to their positions in the stock. BKM Wealth Management LLC purchased a new position in Axon Enterprise in the fourth quarter worth approximately $32,000. Key Financial Inc grew its position in Axon Enterprise by 367.6% in the fourth quarter. Key Financial Inc now owns 159 shares of the biotechnology company’s stock worth $41,000 after acquiring an additional 125 shares during the period. Lindbrook Capital LLC grew its position in Axon Enterprise by 43.3% in the fourth quarter. Lindbrook Capital LLC now owns 172 shares of the biotechnology company’s stock worth $44,000 after acquiring an additional 52 shares during the period. Rakuten Securities Inc. purchased a new position in Axon Enterprise in the fourth quarter worth approximately $48,000. Finally, Principal Securities Inc. purchased a new position in Axon Enterprise in the fourth quarter worth approximately $49,000. 79.08% of the stock is currently owned by hedge funds and other institutional investors.

Axon Enterprise Trading Down 1.7 %

NASDAQ:AXON opened at $279.99 on Friday. The firm has a market cap of $21.13 billion, a PE ratio of 81.87 and a beta of 0.91. The stock has a fifty day moving average price of $306.67 and a 200 day moving average price of $273.57. Axon Enterprise, Inc. has a 12-month low of $175.37 and a 12-month high of $329.87. The company has a current ratio of 2.91, a quick ratio of 2.55 and a debt-to-equity ratio of 0.37.

Axon Enterprise (NASDAQ:AXON) last released its earnings results on Friday, May 10th. The biotechnology company reported $1.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.95 by $0.20. The firm had revenue of $460.74 million during the quarter, compared to analyst estimates of $441.57 million. Axon Enterprise had a return on equity of 11.71% and a net margin of 15.60%. Axon Enterprise’s revenue was up 34.3% compared to the same quarter last year. During the same period last year, the business posted $0.51 earnings per share. Sell-side analysts anticipate that Axon Enterprise, Inc. will post 2.35 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Axon Enterprise news, insider Jeffrey C. Kunins sold 43,668 shares of Axon Enterprise stock in a transaction dated Thursday, May 9th. The stock was sold at an average price of $309.94, for a total transaction of $13,534,459.92. Following the completion of the sale, the insider now directly owns 189,719 shares of the company’s stock, valued at approximately $58,801,506.86. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, Director Jeri Williams sold 308 shares of Axon Enterprise stock in a transaction dated Thursday, May 9th. The stock was sold at an average price of $310.07, for a total transaction of $95,501.56. Following the sale, the director now owns 1,607 shares in the company, valued at $498,282.49. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Jeffrey C. Kunins sold 43,668 shares of Axon Enterprise stock in a transaction dated Thursday, May 9th. The stock was sold at an average price of $309.94, for a total value of $13,534,459.92. Following the sale, the insider now owns 189,719 shares in the company, valued at approximately $58,801,506.86. The disclosure for this sale can be found here. Insiders sold 87,976 shares of company stock valued at $27,268,201 in the last ninety days. Insiders own 6.10% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on AXON shares. Robert W. Baird increased their price objective on Axon Enterprise from $260.00 to $300.00 and gave the stock an “outperform” rating in a research report on Thursday, February 22nd. Argus started coverage on Axon Enterprise in a research report on Wednesday, March 13th. They set a “buy” rating and a $380.00 price target for the company. William Blair restated an “outperform” rating on shares of Axon Enterprise in a research report on Wednesday, April 24th. Barclays raised their price target on Axon Enterprise from $308.00 to $381.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 8th. Finally, JPMorgan Chase & Co. raised their price target on Axon Enterprise from $330.00 to $365.00 and gave the stock an “overweight” rating in a research report on Thursday, April 11th. Two analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Axon Enterprise presently has a consensus rating of “Moderate Buy” and a consensus price target of $335.27.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.